Novartis Reports One Year Results of Beovu (brolucizumabin) in P- III MERLIN Study to Treat Wet Age-Related Macular Degeneration
Shots: The P- III MERLIN study involves assessing the efficacy & safety of Beovu (6 mg, q4w) vs aflibercept (2 mg, q4w) following the loading phase in patients with wet AMD who have persistent retinal fluid despite anti-VEGF therapy Results: met its 1EPs i.e. non-inferiority in mean change in BCVA from baseline and superiority on […]